Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a pharmaceutical company based in China, has entered into another partnership with fellow Chinese firm Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940). The two companies had previously agreed to collaborate on the development of modified drugs and are now expanding their collaboration to focus on drug development strategies that align with future marketing trends. Financial specifics of the partnership were not disclosed.- Flcube.com
Recent news:
-
Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation -
Leman Biotech Enters Zhongshan Life Science Park to Accelerate CAR-T Innovation -
BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline -
Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies -
HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC
